Načítá se...
State of the art in CAR T cell therapy for CD19(+) B cell malignancies
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell malignancies, multiple clinical trials of CAR T cell...
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7108913/ https://ncbi.nlm.nih.gov/pubmed/32235098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129208 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|